Brief Title
Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis
Official Title
Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis
Brief Summary
Adenomyosis was first described as endometrial glands in the myometrium of the uterus. The current definition of adenomyosis is provided in 1972 'the benign invasion of endometrium into the myometrium, producing a diffusely enlarged uterus which microscopically exhibits ectopic non-neoplastic, endometrial glands and stroma surrounded by the hypertrophic and hyperplastic myometrium
Study Phase
Phase 4
Study Type
Interventional
Primary Outcome
The mean pain score after receiving treatment
Condition
Adenomyosis
Intervention
Dienogest
Study Arms / Comparison Groups
Study group
Description: women will receive dienogest
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
100
Start Date
November 2018
Completion Date
March 2020
Primary Completion Date
December 2019
Eligibility Criteria
Inclusion Criteria: - symptomatic adenomyosis - irregular menstrual bleeding and dysmenorrhea . Exclusion Criteria: - asymptomatic patients - - non-lactating patient - not desire for pregnancy - no hormonal treatment more than 6 month even contraception e.g IUD - no focal lesion of uterus (malignancy ,fibroid or adenxal mass )
Gender
Female
Ages
40 Years - N/A
Accepts Healthy Volunteers
No
Contacts
, ,
Administrative Informations
NCT ID
NCT03654144
Organization ID
DINADEN
Responsible Party
Principal Investigator
Study Sponsor
Assiut University
Study Sponsor
, ,
Verification Date
August 2018